2-((3-Allyl-4-oxo-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-2-yl)thio)-N-cyclohexylacetamide

Catalog No. :
ACKRAB394
CAS No. :
314260-59-8
Molecular Formula :
C20H25N3O2S2
Molecular Weight :
403.57

IUPAC Name:2-((3-allyl-4-oxo-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-2-yl)thio)-N-cyclohexylacetamide

2-((3-Allyl-4-oxo-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-2-yl)thio)-N-cyclohexylacetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-((3-Allyl-4-oxo-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-2-yl)thio)-N-cyclohexylacetamide
IUPAC Name2-((3-allyl-4-oxo-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-2-yl)thio)-N-cyclohexylacetamide
Molecular FormulaC20H25N3O2S2
Molecular Weight403.57
SMILESC=CCN1C(C2=C(SC3=C2CCC3)N=C1SCC(NC4CCCCC4)=O)=O
InChI KeyRVYQXBULEMODLG-UHFFFAOYSA-N
Synonym2-((3-allyl-4-oxo-3,5,6,7-tetrahydro-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-2-yl)thio)-N-cyclohexylacetamide;Acetamide, N-cyclohexyl-2-[[3,5,6,7-tetrahydro-4-oxo-3-(2-propenyl)-4H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-2-yl]thio]- (9CI)
CAS No.314260-59-8

Synthetic Route by SureRoute

1. ACKRAB394 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACONEM094 route compound structure diagram
    ACONEM0944998-76-9 In Stock
  4. Then
  5. ACKRAB394 route product structure diagram
    ACKRAB394314260-59-8
Inquiry

2. ACKRAB394 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACKRAB394 route product structure diagram
    ACKRAB394314260-59-8
Inquiry

Comments (0)